About the Journal

Cardiovascular Pharmacology International is a peer-reviewed journal that publishes original basic human studies, original animal studies, and original bench research with potential clinical application to cardiovascular pharmacology and therapeutics. The focus of the experimental studies is translational research. The journal also publishes review articles on basic research, clinical research, editorials, commentaries, points of view, and controversies. Selected journal supplements will also be published. Future focus will include cardioprotective therapies, stem cell therapy, regenerative cardiology, therapies for preventive cardiology (risk factor management), and antiarrhythmic therapies. Selected journal supplements will also be published.

Every informative issue of Cardiovascular Pharmacology International Journal offers cardiologists, clinical pharmacologists and researchers involved in disease relevant clinical and experimental investigations of newer cardiovascular drugs and other therapeutic options.

Six times a year, CPI examines and analyzes arenas such as: Agents that Reduce Myocardial Infarct Size, Agents that Reduce Myocardial Remodeling, Angiotensin Converting Enzyme Inhibitors, Antihypertensive Therapy, Arrhythmias, Atrial Fibrillation, Beta-Blocker Therapies, Cardioembolic Stroke, Cardiomyopathy, Cardioprotective Agents, Cardiopulmonary Resuscitation, Cardiovascular Combination Therapies, Chronic Angina, Chronic Cardiac Ischemia, Congestive Heart Failure, Coronary Artery Disease, Coronary Revascularization, Heparin Therapies, Hypertension, Hypotension Implantable Devices, Ischemic Heart Disease, Myocardial Infarction, Percutaneous Coronary Interventions, Peripheral Arterial Disease, Preconditioning/Postconditioning, Regenerative Cardiology, Stem Cell Therapy.

Among the drug classes regularly evaluated are: ACE inhibitors * angiotensin receptor blockers * anti-anginals * anti-arrhythmics * anti-coagulants * anti-hypertensives * anti-thrombins * beta-blockers * calcium channel blockers * cardioprotective agents * cardiotonic agents * direct renin inhibitors * diuretics * fibrinolytic agents * heart rate modulats * plasminogen activators * QT prolonging drugs * statins * vasoconstrictor agents * and vasodilator agents.

The journal features original articles, topical journal supplements, reviews, clinical and experimental investigations, and commentaries written by respected practitioners from all over the world.

Our Team